Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 28, 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific transaction price of $41.50 per American Depositary Receipt (ADR) within a retirement savings plan.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific increase in the notional allocation of Ordinary share ADRs for a connected person due to a re-valuation of the cash element within the US Retirement Savings Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R (1)(c).
Key Facts for Investor Verification
- Transaction Type: Increase in notional allocation of Ordinary share ADRs.
- Involved Parties: Director Dr. M M Slaoui and Connected Person Dr. K Slaoui.
- Transaction Date: November 25, 2011.
- Transaction Price: $41.50 per ADR.
- Quantity: 5 ADRs.
- Context: Result of a re-valuation of the cash element in the US Retirement Savings Plan.